Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 10/20 | 0.54 |
| ▸ | MMP2 | P08253 | 8/20 | 0.54 |
| ▸ | MMP1 | P03956 | 6/20 | 0.54 |
| ▸ | MMP9 | P14780 | 6/20 | 0.54 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.45 |
| ▸ | UBE2M | P61081 | 4/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16706701 | 0.92 | TSHR (0.44) | MMP13MMP2MMP1MMP9MEP1B | |
| SCHEMBL16706671 | 0.91 | ACHE (0.42) | MMP13MMP2MMP1MMP9MEP1B | |
| SCHEMBL16710029 | 0.89 | PPARG (0.51) | MMP13ALDH1A1TSHRPPARG | |
| SCHEMBL16710032 | 0.89 | PPARG (0.51) | MMP13ALDH1A1TSHRPPARG | |
| SCHEMBL16706737 | 0.88 | UBE2M (0.45) | MMP13MMP2MMP1MMP9MEP1B | |
| SCHEMBL16710037 | 0.88 | NR1H4 (0.46) | MMP13MMP2MMP1MMP9UBE2M | |
| SCHEMBL16706717 | 0.88 | FAAH (0.51) | MMP13MMP2MMP1MMP9UBE2M | |
| SCHEMBL16710099 | 0.87 | NR1H4 (0.45) | MMP13MMP2MMP1MMP9UBE2M | |
| SCHEMBL16710051 | 0.87 | UBE2M (0.44) | MMP13MMP2MMP1MMP9UBE2M | |
| SCHEMBL16710053 | 0.87 | KMT2A (0.45) | MMP13MMP2MMP1MMP9MEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951033-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2018-04-24 | — | — | US | disclosed |
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2017-06-08 | — | — | US | disclosed |
| US-9556111-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2017-01-31 | — | — | US | disclosed |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | TNNI3, TNNT2, MYLK2 | MMP13 4810/4885MMP2 4393/4885MMP1 4549/4885 |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | TNNI3, TNNT2, MYLK2 | MMP13 4844/4885MMP2 4326/4885MMP1 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.